HIV-1 Pseudovirus Neutralisation by a Natural Compound: A Potential Microbicide

**BACKGROUND**
A natural compound isolated from extracts of an indigenous plant in the Eastern Cape, South Africa, showed neutralisation activity against HIV-1 pseudoviruses. The compound can potentially be used in a topical microbicide as an alternative means for women to control the sexual transmission of HIV. The medicinal plant was used by a Traditional Health Practitioner and after a collaboration was set up with CSIR Biosciences, the anti-HIV active compound was isolated. A target based assay (time of addition assay) indicated that the compound acts as an entry inhibitor with the potential use as a topical microbicide. The efficacy of entry inhibitors can be measured with the Luciferase Reporter Gene Assay which detects the inhibition of HIV-1 envelope (env) pseudovirus infection in TZM-bl cells in vitro. The pseudoviral particles are generated in 293T cells through co-transfection of env-expressing plasmids with backbone plasmid DNA. These pseudovirions can infect cells but are unable to reproduce due to an incomplete genome, termed single-round infection. The infections are detected in genetically engineered TZM-bl cells (HeLa cell clones) that express CD4, CXCR4 and endogenous CCR5 and contain a Tatresponsive firefly luciferase gene under the control of an HIV-LTR. The luciferase activity is detected and quantified by luminescence and is proportional to the infectious viral particles that have entered the cell. The specificity of the compound was also determined with this assay against a vesicular stomatitis virus glycoprotein (VSV-G) env pseudovirus. This measured the binding specificity of the compound to HIV while the cytotoxicity of the compound was determined with a MTS assay.

**METHOD**

* DMEM 
* Compound 
* Positive controls 

![Image](Image99x69 to 549x336)

Figure 1: Luciferase Reporter Gene Assay protocol.

![Image](Image99x430 to 808x681)

Figure 2: Molecular cloning of env pseudoviruses.

![Image](100x659)

Figure 3: Principle of Luciferase Reporter Gene Assay in TZM-bl cells.

**RESULTS**

**DISCUSSION AND FUTURE WORK**
Safety and efficacy evaluations in-vitro and in animal models are essential before a potential microbicide can be screened in human clinical trials. The pseudovirus inhibition assay used in this study serves as an early identification step to determine the susceptibility or resistance of the isolates to the potential compound. The compound’s neutralisation activity (IC50 0.1198-7.2µg/mL) against the screened pseudovirions in a Luciferase Reporter Gene Assay seems to be comparable with that of the entry inhibitor T20 (IC50 0.01-2.94µg/mL) and the reverse transcriptase inhibitor Tenofovir (IC50 0.01-0.9125µg/mL). T20 is a more relevant drug for comparative purposes as it is an entry inhibitor and indications on our compound of interest point to it also acting in a similar manner. The mode of action of the compound is, however, yet to be determined. We have shown that the extracts of the plant and the compound are not cytotoxic towards TZM-bl cells when tested in a MTS assay at concentrations up to 100 µg/mL. In addition these did not show any neutralisation activity against VSV-G which has a similar glycoprotein to HIV-1 indicating specificity to HIV-1. The compound will be screened against more HIV-1 subtype C molecular clones to determine the percentage efficacy of the compound to the strains commonly found in sub-Saharan Africa.

**ACKNOWLEDGEMENTS**
CSIR Thematic Funding programme
CSIR Biosciences Aptamer Technology Group

**REFERENCES**